Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($) $ in Thousands |
1 Months Ended | |||
|---|---|---|---|---|
May 31, 2005 |
Mar. 31, 2020 |
Dec. 31, 2019 |
Sep. 30, 2015 |
|
| Long-term debt | ||||
| Debt amount | $ 31,531 | |||
| Novartis Note | ||||
| Long-term debt | ||||
| Research and development expenses funded through loan facility, maximum (as a percent) | 75.00% | |||
| Maximum borrowing capacity under loan agreement | $ 50,000 | |||
| Interest rate at period end (as a percent) | 4.70% | |||
| Amount by which note will be reduced upon achievement of specified milestones | $ 7,300 | |||
| Debt amount | $ 15,900 | $ 15,900 | ||
| Novartis Note | Six-month LIBOR | ||||
| Long-term debt | ||||
| Basis spread on variable rate | 2.00% |
| X | ||||||||||
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available.
|
| X | ||||||||||
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. No definition available.
|
| X | ||||||||||
- Definition The amount by which the note will be reduced upon achievement of specified milestones rather than receiving cash payment under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|